TG Therapeutics Reports Impressive Q3 Growth

TG Therapeutics (NASDAQ: TGTX) revealed remarkable growth during its third-quarter earnings call on November 7, 2024. CEO Michael Weiss announced that BRIUMVI, the company's premier product, achieved US net sales of $83.3 million in Q3, illustrating a 230% increase year-over-year and a 15% rise from the previous quarter. Following these strong results, the company raised its overall sales forecast for BRIUMVI to between $300 million and $305 million, a significant uptick from the earlier prediction of $220 million to $260 million.

Key Takeaways

• BRIUMVI US net sales reached $83.3 million in Q3, marking a 15% sequential climb and over 230% growth year-over-year.
• The full-year sales guidance for BRIUMVI has been elevated to $300 million to $305 million.
• Long-term follow-up from the ULTIMATE I & II and ENHANCE trials indicated 92% of patients experienced no disability progression after five years.
• TG Therapeutics is investigating a 30-minute infusion method and is developing a subcutaneous version of BRIUMVI.
• The company expanded commercialization efforts, engaging nearly 1,100 prescribers and 600 treatment centers.
• Operating costs for the quarter were about $50 million, with approximately $341 million in cash and equivalents by the end of the quarter.

Company Outlook

• TG Therapeutics aspires to establish BRIUMVI as a blockbuster brand and aims to enhance patient outreach and investments in 2025.
• The company holds a 15% market share in the anti-CD20 arena and seeks additional growth.
• New label indications and a subcutaneous formulation of BRIUMVI are in development, with trials anticipated to start in 2024.

Highlights

Bearish:

• Patient enrollment in ongoing trials may proceed slowly.

Bullish:

• Enhanced patient satisfaction as switching from other CD20 therapies to BRIUMVI may not require a loading dose.
• BRIUMVI's strong long-term efficacy and safety bolster its best-in-class reputation.
• The commercial field team has nearly doubled in size over two years to meet rising demand.

Q&A Highlights

• Discussion centered around BRIUMVI's growth potential, competitive dynamics, and plans for label updates and new trials.

TG Therapeutics' robust third-quarter results illustrate solid commercial success and growth potential for BRIUMVI. The company pursues strategic initiatives to expand market presence, innovate formulations, and improve patient experiences, positioning itself for sustained success in the competitive anti-CD20 landscape.

InvestingPro Insights

• TG Therapeutics' stellar Q3 performance aligns with notable revenue growth of 1341.56% year-over-year.
• The company boasts a market capitalization of $3.49 billion and maintains a 92.76% gross profit margin, underscoring its financial strength.
• Trading at a low P/E ratio and a PEG ratio of 0.27 indicates potential undervaluation, marking it as an enticing opportunity for investors.

The company's robust financial standing allows it to invest in clinical and marketing endeavors effectively.

Closing Statements

TG Therapeutics aims to continue expanding BRIUMVI's market reach through commercialization strategies while exploring new indications and advancing their azer-cell therapy. The information discussed lays the groundwork for a promising future ahead.

Available on the Investors & Media section of the TG Therapeutics website for further details on Q3 2024 results.